- ProQR Therapeutics NV R&D Day TranscriptMar 29, 2023
- ProQR Therapeutics NV Lilly Partnership Expansion and Axiomer Overview TranscriptDec 22, 2022
- ProQR Therapeutics NV Management Call TranscriptAug 11, 2022
- ProQR Therapeutics NV Additional Sepofarsen Analyses and Company Strategy Update Call TranscriptApr 13, 2022
- ProQR Therapeutics NV Top-Line Results Phase 2/3 Illuminate Trial - Corporate Call TranscriptFeb 11, 2022
- ProQR Therapeutics NV Analyst Event TranscriptNov 18, 2021
- ProQR Therapeutics NV at Chardan Genetic Medicines Conference (Virtual) TranscriptOct 05, 2021
- ProQR Therapeutics NV at Citi BioPharma Conference (Virtual) TranscriptSep 09, 2021
- ProQR Therapeutics NV Axiomer RNA Call TranscriptSep 09, 2021
- ProQR Therapeutics NV Review of Phase 1/2 Stellar Data in Usher/nsRP Hosted By Cantor Fitzgerald TranscriptMar 25, 2021
- ProQR Therapeutics NV to Discuss the Results of Phase 1/2 Stellar trial of QR-421a in Adults with Usher Syndrome and nSRP TranscriptMar 24, 2021
- ProQR Therapeutics NV at H C Wainwright Global Life Sciences Conference (Virtual) TranscriptMar 09, 2021
- ProQR Therapeutics NV Expert Perspectives Call TranscriptFeb 22, 2021
- Apellis Pharmaceuticals Inc, Aerie Pharmaceuticals, Aldeyra Therapeutics, and ProQR Therapeutic at Citi BioPharma Conference (Virtual) - Panel TranscriptSep 10, 2020
- ProQR Therapeutics NV Expert Perspectives Series -- LCA10 and Sepofarsen - Call TranscriptJul 20, 2020
- ProQR Therapeutics NV Expert Perspectives Series -- Usher Syndrome and Retinitis Pigmentosa - Call TranscriptJun 22, 2020
ProQR Therapeutics NV Expert Perspectives Call Transcript
Good afternoon, and welcome to the ProQR Expert Perspectives Call. (Operator Instructions) Today's call is being recorded, and a replay will be made available on the ProQR website following the event.
At this time, I would like to turn the call over to Daniel de Boer, Founder and Chief Executive Officer of ProQR for some introductory remarks. Please go ahead, Daniel.
Thank you, Sarah, and good afternoon, and good morning, everyone, wherever you are. Welcome to today's expert perspective call. At ProQR, we work every day to create transformative RNA therapies for severe genetic and rare indications.
For those on the call today that may be just learning about us, we are a biotechnology company that is headquartered in Leiden in the Netherlands, and we have a U.S. site in Cambridge, Massachusetts. While our RNA oligonucleotides platform has brought applicability, our focus is on the development of medicines for inherited retinal diseases.
We have a
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)